Screener
Haemonetics HAE MedSurg — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
|---|---|---|
| Cost of goods sold | $50,368 | $50,216 |
| Selling, general and administrative | 65,160 | 62,323 |
| Research and development | 9,820 | 8,742 |
| MedSurg operating income | $22,714 | $18,377 |
| Corporate and unallocated expenses | ||
| Amortization of acquired assets | $(10,204) | $(13,828) |
| Integration and transaction costs | (2,719) | (2,682) |
| Restructuring and restructuring related costs | (2,258) | (1,324) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's medsurg — operating income (loss)?
- Haemonetics (HAE) reported medsurg — operating income (loss) of $22.71M in Q2 2026.
- What does medsurg — operating income (loss) mean?
- Calculated as the segment's total net revenues minus its cost of goods sold and operating expenses, representing the core profitability of the MedSurg business. This is the primary metric for evaluating the segment's ability to generate sustainable earnings from its operations.
Ask your AI about Haemonetics's medsurg — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude